MAIA Biotechnology, Inc. (MAIA)
NYSE American
Price as at 30 Sept 2026, 21:00 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
MAIA Biotechnology, Inc. trades at $1.18. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its MAIA data?
Fundamentals for MAIA come from company filings and exchange data, as listed on NYSE American; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 21:00 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for MAIA, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.